485 related articles for article (PubMed ID: 33713596)
1. NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Adler AI; Douch E; Dunning L; Elliott N
Lancet Diabetes Endocrinol; 2021 May; 9(5):261-263. PubMed ID: 33713596
[No Abstract] [Full Text] [Related]
2. Dapagliflozin in patients with heart failure and reduced ejection fraction.
Colombo G; Casella R; Cazzaniga A; Casiraghi C;
Intern Emerg Med; 2020 Apr; 15(3):515-517. PubMed ID: 32124206
[No Abstract] [Full Text] [Related]
3. Dapagliflozin Cut Risk of Worsening Heart Failure.
Slomski A
JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
[No Abstract] [Full Text] [Related]
4. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Bhatt DL; Verma S; Braunwald E
Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
[TBL] [Abstract][Full Text] [Related]
5. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
Verma S
Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505
[No Abstract] [Full Text] [Related]
6. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
[No Abstract] [Full Text] [Related]
9. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
[TBL] [Abstract][Full Text] [Related]
10. Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
Naser JA; Tada A; Harada T; Reddy YNV; Carter RE; Testani JM; Jensen MD; Borlaug BA
Circulation; 2024 Jun; 149(25):2026-2028. PubMed ID: 38885297
[No Abstract] [Full Text] [Related]
11. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin (Jardiance) for heart failure.
Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
[No Abstract] [Full Text] [Related]
14. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
15. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin Safe and Effective for Heart Failure With Frailty.
Slomski A
JAMA; 2022 May; 327(20):1950. PubMed ID: 35608583
[No Abstract] [Full Text] [Related]
17. Follow the EMPULSE: In-hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction.
Lien T; Srikanth K; Ambrosy AP
Eur J Heart Fail; 2024 Apr; 26(4):971-973. PubMed ID: 38654440
[No Abstract] [Full Text] [Related]
18. Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.
Tingen J; Gazewood JD
Am Fam Physician; 2020 Jul; 102(2):115-116. PubMed ID: 32667164
[No Abstract] [Full Text] [Related]
19. Is Dapagliflozin Cost-effective for Treating Heart Failure?
Slomski A
JAMA; 2021 Aug; 326(5):378. PubMed ID: 34342627
[No Abstract] [Full Text] [Related]
20. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
